It revealed that ICAM1+ MDM marker genes progressively increased, whereas GPNMB+ MDM marker genes gradually decreased in both neoadjuvant therapy non-responders and newly diagnosed GBM patients (Fig. 5D). This evidence concerns the gene GPNMB and glioblastoma.